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Q  Which patients with metabolic 
syndrome benefit from metformin?
 patients at highest risk for 
 progression to diabetes benefit 
from metformin. 
In patients with metabolic syndrome 
who are in the highest-risk quartile for 
progression to diabetes (predicted mean 
3-year risk, 60%), metformin, 850 mg 
twice daily, reduces the absolute risk by 
about 20% over a 3-year period. Metformin 
doesn’t reduce the incidence in patients at 
lower risk of progression (strength of rec-
ommendation [SOR]: C, post-hoc analysis 
of a randomized controlled trial [RCT]). 
Intensive lifestyle modification 
reduces absolute risk in all patients pro-
portionate to risk quartile (from 5% reduc-
tion for the lowest quartile to 28% for the 
highest). Over a 10-year period, intensive 
lifestyle modification reduces the abso-
lute risk of diabetes by 34% and metformin 
reduces the risk by 18% for all patients at 
increased risk (considered as a group)—
that is, not separated by risk quartile (SOR: 
A, large prospective RCTs).
Lower doses or shorter courses of 
metformin reduce fasting plasma glucose 
(SOR: C, RCTs with laboratory outcomes) 
and may reduce the risk of developing dia-
betes by a smaller amount (SOR: C, flawed 
RCT).
Evidence summary
A post-hoc analysis of a prospective RCT 
(the Diabetes Prevention Program) com-
prising 3081 patients with impaired glucose 
metabolism who received metformin, a 
lifestyle modification program, or no inter-
vention (placebo) found that metformin 
reduced the risk of developing diabetes only 
for patients in the highest risk quartile over 
2.8 years. Lifestyle modification reduced dia-
betes risk in all patients.1 
Investigators stratified patients who 
met National Cholesterol Education Pro-
gram Adult Treatment Panel III (NCEP ATP 
III) criteria for metabolic syndrome into risk 
quartiles for progression to diabetes using a 
model they developed based on 7 parameters: 
fasting plasma glucose, hemoglobin A1c, his-
tory of high blood glucose, waist:hip ratio, 
waist circumference, triglycerides, and height 
(TABLE1). The model reasonably fit outcomes—
the percentage of patients in each quartile 
who developed diabetes—with an area under 
the receiver operator characteristic curve of 
0.73 (a measure of diagnostic accuracy where 
1 is a perfect predictor and 0.5 is random). 
The researchers then used the model to 
calculate the protective effect of metformin 
(850 mg twice daily) and lifestyle modifica-
tion (16 lessons on diet and exercise with a 
case manager). Metformin reduced the rate 
of developing diabetes only among patients 
in the highest risk quartile, whose mean 
3-year diabetes risk averaged 60% (placebo 
rate=59.6%; metformin rate=38.2%; mean 
absolute risk reduction [ARR]=21.4%; 3-year 
number needed to treat [NNT]=4.6). 
Lifestyle modification reduced risk 
in all quartiles with progressively greater 
effect as risk increased (lowest risk quartile: 
ARR=4.9%, 3-year NNT=20.4; highest risk 
quartile: ARR=28.3%; 3-year NNT=3.5). 
There were 2 key weaknesses of the risk 
model: It wasn’t validated in a separate popula-
tion and the true incidence of diabetes among 
patients taking placebo was higher than pre-
dicted. The investigators compared their risk 
prediction model results with the Framingham 
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Risk Score (FRS) for diabetes and found that 
they correlated well, although the FRS results 
were consistently about 6% (absolute) higher 
when corrected for duration. (The FRS calcu-
lator is available online at www.framingham-
heartstudy.org/risk-functions/diabetes/.)
Lifestyle change reduces diabetes risk   
more than metformin
The original Diabetes Prevention Program 
found that intensive lifestyle intervention and 
metformin reduced the number of diabetes 
cases over 2.8 years among 3234 patients at 
risk for developing diabetes.2 
Compared with no intervention, fewer 
patients developed diabetes with either met-
formin or lifestyle improvement, although 
lifestyle change had the larger effect (no 
intervention: 11 cases per 100 person-
years; metformin: 7.8 cases; 95% confidence 
interval [CI], 6.8-8.8; ARR=3.2% per year vs 
no intervention; lifestyle improvements: 
4.8 cases; 95% CI, 4.1-5.7; ARR=6.2% per year 
vs no intervention). 
The effect of metformin and  
lifestyle change persists at 10 years
A 10-year follow-up study to the Diabe-
tes Prevention Program found that, com-
pared with no intervention, both metformin 
and lifestyle interventions continued to be 
associated with a lower incidence of diabetes 
(no intervention: 7.8 cases per 100 person-
years; 95% CI, 4.8-6.5; metformin: 6.4 cases; 
95% CI, 4.2-5.7; ARR=1.4% per year; lifestyle 
interventions: 5.3 cases; 95% CI, 5.1-6.8; 
ARR=2.5% per year).3 
Researchers originally randomized 3234 
patients with body mass index ≥24 kg/m2, 
fasting blood sugar 95 to 125 mg/dL, and 
2-hour post 75-gm glucose value of 149 to 
199 mg/dL to 3 groups: intensive lifestyle 
modification (weight loss goal of 7%, 
150 minutes a week of exercise), metfor-
min (850 mg twice daily), and no inter 
vention. After the 2.8-year follow-up period, 
2766 patients continued for another 
5.7 years of follow-up. Investigators offered 
group lifestyle counseling to all patients and 
continued metformin at the same dose in the 
second group.
Earlier study shows an effect  
for metformin, but with a caveat
An earlier RCT found that metformin reduced 
the risk of developing diabetes in patients 
TABLE 
Effect of metformin, lifestyle modification on development  
of diabetes over 3 years in patients with metabolic syndrome*1
Intervention Diabetes 
rate, risk 
quartile 1**
HR (95% CI) Diabetes 
rate, risk 
quartile 2
HR  
(95% CI)
Diabetes 
rate, risk 
quartile 3
HR (95% CI) Diabetes 
rate, risk 
quartile 4
HR  
(95% CI)
Placebo 8.3% 17.8% 29.1% 59.6%
Metformin  
(850 mg twice 
daily)
9.6% 1.07  
(0.57-2.01)
14.9% 0.79  
(0.49-1.28)
24.4% 0.82  
(0.57-1.18)
38.2% 0.44  
(0.33-0.59)
Lifestyle  
modification
3.4% 0.30  
(0.12-0.75)
8.6% 0.45  
(0.26-0.79)
15.5% 0.43  
(0.28-0.67)
31.3% 0.34  
(0.25-0.46)
CI, confidence interval; HR, hazard ratio.
*Significant outcomes in bold.
**Patients in the highest diabetes risk quartile had >137 total points (sum of 7 parameters).1 Points were awarded as follows: 
1. Fasting plasma glucose: 0.18 points per mg/dL for range from above 90 to 140 (0 points for 90; 18 points for 100 mg/dL).
2. Hemoglobin A1c: 16.7 points for each percentage point for range from above 3% to 9% (0 points for 3%; 16.7 points for 4%).
3. History of high blood glucose: 13 points if positive.
4. Triglycerides: 0.054 points per mg/dL from 0 to 1000 mg/dL, to a maximum of 54 points (11 points for triglycerides of 200 mg/dL).
5. Waist circumference: 0.273 points per cm from 60 to 210 cm, to a maximum of 41 points (0 points for 60 cm; 27.3 points for 160 cm).
6. Height: 0.375 points per cm in reverse order from 200 to 120 cm (0 points for 200 cm; 30 points for 120 cm).
7. Waist-to-hip ratio: 0.031 points per unit from ratio of 0.5 to 2, to a maximum of 64 points (0 points for ratio of 0.5; 64 points for ratio of 2).
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with metabolic syndrome.4 Investigators ran-
domized 70 patients to metformin (250 mg 
3 times daily) or placebo for a year. Fewer 
patients developed diabetes with metformin 
(3% vs 16.2%, P=.011; NNT=7.6) and more 
had a normal glucose tolerance test result 
(84.9% vs 51.4%, P=.011; NNT=3). However, 
by current American Diabetes Association 
criteria, half of the subjects had early diabe-
tes at baseline.
Metformin lowers fasting blood sugar,  
but may not reverse metabolic syndrome
A post-hoc analysis of another RCT found 
that metformin reduced fasting plasma glu-
cose (FPG) levels in patients with upper-body 
obesity and metabolic syndrome (by 1999 
World Health Organization criteria but not 
NCEP ATP III criteria).5 
Investigators randomized 457 patients 
to metformin 850 mg once daily or placebo 
and followed them for a year. FPG levels 
decreased with metformin but increased 
with placebo (reduction FPG 5.9 mg/dL vs 
increase FPG 12.3 mg/dL; P<.04). The inves-
tigators didn’t report whether any patients 
developed diabetes.
However, another RCT (155 patients) 
that compared metformin 850 mg twice daily 
with placebo in subjects with metabolic syn-
drome but without diabetes found greater 
normalization of FPG (5% vs 0%; P=.005), but 
no reversal of metabolic syndrome or change 
in Framingham 10-year risk score after 
12 weeks.6                   JFP
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